Similar articles

• Cost considerations in therapy with myeloid growth factors.

  Glaspy JA, Jakway J. Glaspy JA, et al. Am J Hosp Pharm. 1993 Jul;50(7 Suppl 3):S19-26. Am J Hosp Pharm. 1993. PMID: 7689789 Review.
• Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.

  Cernelc P, Andoljsek D, Mlakar U, Pretnar J, Modic M, Zupan IP, Zver S. Cernelc P, et al. Pflugers Arch. 2000;440(5 Suppl):R81-2. Pflugers Arch. 2000. PMID: 11005621
• Clinical trials of myeloid growth factors.

  Glaspy JA, Golde DW. Glaspy JA, et al. Exp Hematol. 1990 Nov;18(10):1137-41. Exp Hematol. 1990. PMID: 1698650 Review. No abstract available.
• Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.

  Bhana N. Bhana N. Curr Opin Oncol. 2007 Jul;19(4):328-35. doi: 10.1097/01.cco.0000275309.58868.11. Curr Opin Oncol. 2007. PMID: 17545795 Review.
• The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma.

  Rabinowe SN, Nemunaitis J, Armitage J, Nadler LM. Rabinowe SN, et al. Semin Hematol. 1991 Apr;28(2 Suppl 2):6-16. Semin Hematol. 1991. PMID: 1712125 Review. No abstract available.